Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety of TT-00420 Monotherapy in Patients With Advanced Solid Tumors and Triple Negative Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03654547
Recruitment Status : Recruiting
First Posted : August 31, 2018
Last Update Posted : August 20, 2020
Sponsor:
Information provided by (Responsible Party):
TransThera Biosciences Co., Ltd

Brief Summary:
This is a first-in-human, phase I clinical research study with TT-00420, an investigational, oral, multi-target, dual mechanism kinase inhibitor targeting both mitosis and tumor micro-environment, for the treatment of triple negative breast cancer (TNBC) and other advanced solid tumors. The study consists of a dose escalation part followed by a MTD expansion part.

Condition or disease Intervention/treatment Phase
Advanced Solid Tumors Triple Negative Breast Cancer Drug: TT-00420 Phase 1

Detailed Description:

Dose Escalation Cohorts: Eligible adult patients with advanced solid tumors will be enrolled into Dose Escalation cohorts. Starting dose of TT-00420 mono-therapy will be 1 mg p.o., q.d. TT-00420 capsule will be administered once daily on a continuous schedule. A treatment cycle consists of 28 days. An ABLRM guided by the EWOC principle will evaluate the risk of under-dose or over-dose for the dose tested in each cohort and provide the recommendation dose for next cohort. Dose limiting toxicity (DLT) will be evaluated per the pre-defined DLT criteria and managed by the pre-defined rules detailed in the protocol. Maximum Tolerated Dose (MTD) and/or Dose Recommend for Dose Expansion (DRDE) will be determined in Dose Escalation cohorts.

Dose Expansion Cohorts:

TNBC Cohort:

TNBC Dose-Expansion cohort will be opened to enroll the patients with advanced TNBC and evaluate the safety, PK and preliminary efficacy of TT-00420 to identify the optimal biological dose (OBD), when feasible, in patients with advanced TNBC.

SAT Cohort:

A parallel basket SAT Dose Expansion Cohort will be open to enroll patients with selected advanced tumors (SAT) to evaluate the safety, PK and preliminary efficacy of TT-00420 to identify the optimal biological dose (OBD), when feasible, in patients with SATs.

Recruitment in dose expansion cohorts may be put on hold if any significant safety finding(s) that was not observed in dose escalation cohorts is identified. Bayesian modeling will be updated with the new findings to evaluate if the previously determined MTD or DRDE still suitable for further enrollment.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 75 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Intervention Model Description: Dose Escalation arm followed by Dose Expansion arm
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I, First-In-Human, Multicenter, Open-Label Study of TT-00420, Administered Orally in Adult Patients With Advanced Solid Tumors and Triple Negative Breast Cancers
Actual Study Start Date : January 8, 2019
Estimated Primary Completion Date : March 31, 2021
Estimated Study Completion Date : September 30, 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Arm Intervention/treatment
Experimental: Dose Escalation
Eligible adult patients with advanced solid tumors will be enrolled into Dose Escalation cohorts and treated with TT-00420 at different dose cohorts. Starting dose will be 1 mg p.o., q.d. An ABLRM guided by the EWOC principle will evaluate the risk of under-dose or over-dose for the dose tested in each cohort and provide the recommendation dose for next cohort. Dose Escalation Teleconference will be held after the last evaluable patient complete Cycle 1 treatment in each dose cohort to evaluate DLT, determine MTD and/or DRDE.
Drug: TT-00420

TT-00420 is an investigational, oral, multi-target, dual mechanism kinase inhibitor targeting both mitosis and tumor microenvironment, for the treatment of triple negative breast cancer (TNBC) and other advanced solid tumors.

TT-00420 capsule will be administered once daily on a continuous schedule. A treatment cycle consists of 28 days.

The proposed dosage form for early clinical research is powder filled hard gelatin capsule (PIC) with dosage strengths as of 1 mg, 5 mg and 20 mg.


Experimental: Dose Expansion

TNBC Cohort: TNBC Dose-Expansion cohort will be opened to enroll the patients with advanced TNBC and evaluate the safety, PK and preliminary efficacy of TT-00420 and identify the optimal biological dose (OBD), when feasible, in patients with advanced TNBC.

SAT Cohort: A parallel basket SAT Dose Expansion Cohort will be open to enroll patients with SATs to evaluate the safety, PK and preliminary efficacy of TT-00420 and identify the optimal biological dose (OBD), when feasible, in patients with SATs.

Drug: TT-00420

TT-00420 is an investigational, oral, multi-target, dual mechanism kinase inhibitor targeting both mitosis and tumor microenvironment, for the treatment of triple negative breast cancer (TNBC) and other advanced solid tumors.

TT-00420 capsule will be administered once daily on a continuous schedule. A treatment cycle consists of 28 days.

The proposed dosage form for early clinical research is powder filled hard gelatin capsule (PIC) with dosage strengths as of 1 mg, 5 mg and 20 mg.





Primary Outcome Measures :
  1. Maximum Tolerated Dose (MTD) and/or Dose Limiting Toxicity (DLT) [ Time Frame: At the end of Cycle 1 (each cycle is 28 days) ]
    FIH Dose Finding


Secondary Outcome Measures :
  1. Dose Recommended for Dose Expansion (DRDE) [ Time Frame: At the end of Cycle 1 (each cycle is 28 days) ]
    Dose Recommended for Dose Expansion

  2. Optimal Biological Dose (OBD) [ Time Frame: At the end of Cycle 1 (each cycle is 28 days) ]
    Dose Recommended for Dose Expansion

  3. Number of Participants With Abnormal Laboratory Values [ Time Frame: Up to 30 days from study discontinuation ]
    Safety and tolerability of TT-00420

  4. Number of Participants With Adverse Events That Are Related to Treatment [ Time Frame: Up to 30 days from study discontinuation ]
    Safety and tolerability of TT-00420

  5. Peak Plasma Concentration (Cmax) of TT-00420 [ Time Frame: through study completion, an average of 6 months ]
    PK parameters of TT-00420

  6. Time at which Cmax was first observed (Tmax) of TT-00420 [ Time Frame: through study completion, an average of 6 months ]
    PK parameters of TT-00420

  7. Half-life (T1/2) of TT-00420 [ Time Frame: through study completion, an average of 6 months ]
    PK parameters of TT-00420

  8. Objective Response Rate (ORR) [ Time Frame: through study completion, an average of 1 year ]
    ORR of TT-00420 in patients with TNBC or SAT treated in Dose Expansion cohorts

  9. Disease Control Rate (DCR) [ Time Frame: through study completion, an average of 1 year ]
    DCR of TT-00420 in patients with TNBC or SAT treated in Dose Expansion cohorts

  10. Duration of Response (DOR) [ Time Frame: through study completion, an average of 1 year ]
    DOR of TT-00420 in patients with TNBC or SAT treated in Dose Expansion cohorts

  11. Progression Free Survival (PFS) [ Time Frame: through study completion, an average of 1 year ]
    PFS of TT-00420 in patients with TNBC or SAT treated in Dose Expansion cohorts

  12. Overall Survival (OS) [ Time Frame: through study completion, an average of 1 year ]
    OS of TT-00420 in patients with TNBC or SAT treated in Dose Expansion cohorts


Other Outcome Measures:
  1. Exploratory Biomarker Assay [ Time Frame: through study completion, an average of 6 months ]
    TNBC subtype; pH3, angiogenesis, p-STAT3 etc.; MSI, TMB



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Aged 18 years to 75 years at the time of provision of informed consent
  2. Dose Escalation Cohorts: Histopathological or cytologically documented locally advanced or metastatic solid tumors who have no available standard therapeutic treatment options Dose Expansion Cohorts: Histopathological or cytologically documented locally advanced or metastatic TNBC or SATs
  3. TNBC Dose Expansion Cohort:

    1. Histologically proven invasive breast carcinoma with triple negative receptor status per institutional standard and with confirmed negative for ER and PR by IHC (<10% positive tumor nuclei)
    2. relapsed/refractory to at least one line of systemic chemotherapy
  4. At least one measurable lesion as defined by RECIST V1.1 criteria for solid tumors
  5. ECOG performance status of 0 or 1
  6. Adequate organ function confirmed at Screening and within 10 days of initiating treatment, as evidenced by:

    • Absolute Neutrophil Count (ANC) ≥ 1.5 x 10^9/L
    • Hemoglobin (Hgb) ≥ 9 g/dl
    • Platelets (plt) ≥ 100 x 10^9/L
    • AST/SGOT and ALT/SGPT ≤ 2.5 x Upper Limit of Normal (ULN) or ≤ 5.0 x ULN if liver metastases are present
    • Total bilirubin ≤ 1.5 x ULN, or direct bilirubin < ULN for patients with total bilirubin levels >1.5 ULN
    • Serum creatinine ≤ 1.5 x ULN or calculated 24-hour clearance ≥ 50 mL/min
    • Negative pregnancy test within 72 hours before starting study treatment in all pre-menopausal women and women < 12 months after the onset of menopause
  7. Must agree to take sufficient contraceptive methods to avoid pregnancy during the study and until at least 6 months after ceasing study treatment
  8. Able to sign informed consent and to comply with the protocol

Exclusion Criteria:

  1. Women who are pregnant or lactating
  2. Women of child-bearing potential (WOCBP) who does not use adequate birth control
  3. Patients with any hematologic malignancy. This includes leukemia (any form), lymphoma, and multiple myeloma.
  4. Patients with

    1. a history of primary central nervous system tumors or
    2. carcinomatous meningitis Note: Patients with treated brain metastases that are off corticosteroid and have been clinically stable 28 days are eligible for enrollment
  5. Patients with the following mood disorders as judged by the Investigator or a psychiatrist, or as result of patient's mood assessment questionnaire:

    • Medically documented history of or active major depressive episode, bipolar disorder (I or II), obsessive-compulsive disorder, schizophrenia; a history of suicidal attempt or ideation, or homicidal ideation (immediate risk of doing harm to others)
    • ≥ CTCAE grade 3 anxiety
    • The psychiatric judgment, if available, overrules the mood assessment questionnaire result/investigator judgment
  6. Impaired cardiac function or clinically significant cardiac diseases, including but not limited to any of the following:

    1. LVEF < 45% as determined by MUGA scan or ECHO
    2. Congenital long QT syndrome
    3. QTc ≥ 450 msec on screening ECG
    4. Unstable angina pectoris ≤ 3 months prior to starting study drug
    5. Acute myocardial infarction ≤ 3 months prior to starting study drug
  7. Patients with

    1. unresolved diarrhea ≥ CTCAE grade 2, or
    2. impairment of gastrointestinal (GI) function, or
    3. GI disease that may significantly alter the absorption of TT-00420 (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection).
  8. Other concurrent severe and/or uncontrolled concomitant medical conditions (e.g., uncontrolled hypertriglyceridemia [triglycerides > 500 mg/dL], active or uncontrolled infection) that could cause unacceptable safety risks or compromise compliance with the protocol
  9. Patients who have received chemotherapy, targeted therapy or immunotherapy ≤ 4 weeks (6 weeks for nitrosourea or mitomycin-C) prior to starting study drug or who have not recovered from side effects of such therapy
  10. Patients who have received wide field radiotherapy ≤ 4 weeks or limited field radiation for palliation ≤ 2 weeks prior to starting study drug or who have not recovered from side effects of such therapy
  11. Patients who have undergone major surgery ≤ 4 weeks prior to starting study drug or who have not recovered from side effects of such therapy
  12. Patients who have been treated with any hematopoietic colony-stimulating growth factors (e.g., G-CSF, GM-CSF) ≤ 2 weeks prior to starting study drug. Erythropoietin or darbepoetin therapy, if initiated before enrollment, may be continued
  13. Patients who are currently receiving treatment with therapeutic doses of warfarin sodium (Coumadin®) or any other coumarin-derivative anticoagulants
  14. Patients who have received corticosteroids ≤ 2 weeks prior to starting study drug or who have not recovered from the side effects of such treatment
  15. Patients who are currently receiving treatment with medication that has known risk to prolong the QT interval or inducing Torsades de Pointes, and the treatment cannot either be discontinued or switched to a different medication prior to starting study drug
  16. Patients who are receiving high to moderate CYP3A inhibitors and inducers as listed in Appendix F
  17. Known diagnosis of human immunodeficiency virus (HIV) infection (HIV testing is not mandatory)
  18. Known history of active infection with Hepatitis B (e.g., HBsAg reactive), or Hepatitis C (e.g., HCV RNA (qualitative) is detected)
  19. Has received a live-virus vaccination within 30 days of planned first dose Note: Seasonal flu vaccines are permitted.
  20. Inability to swallow or tolerate oral medication
  21. Has a history or current evidence of any condition, therapy, or laboratory abnormality that, in the opinion of the investigator, might confound the results of the trial, interfere with the patient's participation and compliance in the trial

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03654547


Contacts
Layout table for location contacts
Contact: Peng Peng, Ph.D. 86 25 86901107 peng_peng@transtherabio.com
Contact: Hui Wang 86 25 86901159 wang_hui@transtherabio.com

Locations
Layout table for location information
United States, Texas
MD Anderson Cancer Center Recruiting
Houston, Texas, United States, 77030
Contact: Rabia Khan       rkhan@mdanderson.org   
Principal Investigator: Sarina A Piha-Paul, MD         
Sponsors and Collaborators
TransThera Biosciences Co., Ltd
Investigators
Layout table for investigator information
Principal Investigator: Sarina A. Piha-Paul, MD M.D. Anderson Cancer Center
Layout table for additonal information
Responsible Party: TransThera Biosciences Co., Ltd
ClinicalTrials.gov Identifier: NCT03654547    
Other Study ID Numbers: TT420X2101
First Posted: August 31, 2018    Key Record Dates
Last Update Posted: August 20, 2020
Last Verified: August 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Triple Negative Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases